Study of PRA-216 for COPD patients
Part of Lungs & breathing clinical trials.
This study tests an investigational drug called PRA-216 in people with COPD. The goal is to see if it is safe and to look at certain markers in the body that might show how the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have had a COPD diagnosis for at least 12 months.
- You are currently taking COPD medications at a stable dose for at least 2 months.
- You do not have other significant lung conditions besides COPD.
- You have not had major surgery in the past 8 weeks.
- You have not used certain antibody therapies in the past 4 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medication for chronic obstructive pulmonary disease (COPD) in two parts: first in healthy volunteers, then in people with COPD. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This study looks at how the immune system works and how well diseases like asthma, COPD, and others are controlled. You may join if you have one of these conditions or if you are a healthy volunteer or smoker without lung disease.
This study tests an investigational drug called PRA-216, first in healthy volunteers to check safety, then in people with mild-to-moderate asthma to see if it helps control symptoms. It's an early-stage trial to find out if the drug is safe and works.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.